Schramme, F., Crosignani, S., Frederix, K., Hoffmann, D., Pilotte, L., Stroobant, V., . . . Van Den Eynde, B. (2019). Inhibition of tryptophan-dioxygenase activity increases the antitumor efficacy of immune checkpoint inhibitors. American Association for Cancer Research.
Citación estilo ChicagoSchramme, F., S. Crosignani, K. Frederix, D. Hoffmann, L. Pilotte, V. Stroobant, J. Preillon, G. Driessens, and B. Van Den Eynde. Inhibition of Tryptophan-dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors. American Association for Cancer Research, 2019.
Cita MLASchramme, F., et al. Inhibition of Tryptophan-dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors. American Association for Cancer Research, 2019.